Trial Profile
Phase 1 Safety and Pharmacokinetics of Methane Sulfonylfluoride (MSF or SNX-001) After Single and Multiple Oral Dose Administration in Healthy Adult Aged Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2015
Price :
$35
*
At a glance
- Drugs Methanesulfonyl fluoride (Primary)
- Indications Alzheimer's disease; Cognition disorders
- Focus Adverse reactions
- Sponsors SeneXta Therapeutics
- 01 Nov 2012 Results published in the British Journal of Clinical Pharmacology.
- 06 Jan 2011 New trial record